Dr. Jennifer Lingler’s research sited in news article on ALZFORUM

To Know or Not to Know: Trial Participants Confront the Question

As large international study cohorts and clinical trials seek to enroll participants in the earliest stages, they must rely on biomarkers—such as amyloid accumulation in the brain or possession of the ApoE4 allele—rather than outward cognitive symptoms. This means that inviting someone to join such a trial equates to disclosing their AD risk status to them.